Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Urinary Bladder | 2 | 2018 | 170 | 0.78 | Why? |
| Fiducial Markers | 1 | 2017 | 8 | 0.70 | Why? |
| Radiotherapy, Image-Guided | 1 | 2017 | 77 | 0.66 | Why? |
| Radiotherapy, Intensity-Modulated | 1 | 2017 | 148 | 0.63 | Why? |
| Radiation Injuries | 1 | 2017 | 140 | 0.58 | Why? |
| Hospitals, General | 1 | 2017 | 711 | 0.46 | Why? |
| Continuous Positive Airway Pressure | 1 | 2020 | 1187 | 0.45 | Why? |
| Consensus | 4 | 2020 | 6345 | 0.44 | Why? |
| Prostatic Neoplasms | 2 | 2018 | 1637 | 0.35 | Why? |
| Point-of-Care Testing | 1 | 2020 | 2782 | 0.33 | Why? |
| Antigens, Viral | 2 | 2021 | 6298 | 0.32 | Why? |
| Vitamin D Deficiency | 1 | 2017 | 1782 | 0.26 | Why? |
| Liver Diseases | 1 | 2018 | 2698 | 0.25 | Why? |
| Telomere Shortening | 1 | 2021 | 66 | 0.21 | Why? |
| Venous Thromboembolism | 1 | 2018 | 4273 | 0.20 | Why? |
| Hospital Mortality | 3 | 2019 | 22087 | 0.19 | Why? |
| Telomere | 1 | 2021 | 146 | 0.19 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.19 | Why? |
| Pneumocystis carinii | 1 | 2020 | 205 | 0.18 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.17 | Why? |
| Lactates | 1 | 2017 | 59 | 0.17 | Why? |
| Prostatic Neoplasms, Castration-Resistant | 1 | 2018 | 109 | 0.17 | Why? |
| Acute Kidney Injury | 1 | 2017 | 5762 | 0.16 | Why? |
| Movement | 1 | 2018 | 232 | 0.16 | Why? |
| Spain | 6 | 2021 | 15545 | 0.16 | Why? |
| Macrophage Activation Syndrome | 1 | 2020 | 342 | 0.15 | Why? |
| Pneumonia, Pneumocystis | 1 | 2020 | 322 | 0.15 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.15 | Why? |
| Rectum | 1 | 2018 | 495 | 0.14 | Why? |
| Hospital Administration | 1 | 2021 | 650 | 0.13 | Why? |
| Teaching Rounds | 1 | 2017 | 208 | 0.13 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.13 | Why? |
| Critical Illness | 1 | 2017 | 17281 | 0.13 | Why? |
| Societies, Scientific | 1 | 2017 | 414 | 0.13 | Why? |
| Immunoglobulin M | 2 | 2021 | 9091 | 0.12 | Why? |
| Internal Medicine | 1 | 2018 | 557 | 0.12 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.11 | Why? |
| Family Practice | 1 | 2018 | 472 | 0.11 | Why? |
| Nasopharynx | 2 | 2021 | 10224 | 0.11 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.11 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.10 | Why? |
| Phosphoproteins | 1 | 2021 | 4346 | 0.10 | Why? |
| National Health Programs | 1 | 2017 | 807 | 0.10 | Why? |
| Radiation Oncology | 1 | 2018 | 834 | 0.10 | Why? |
| Pancreatic Neoplasms | 1 | 2017 | 609 | 0.10 | Why? |
| Symptom Assessment | 2 | 2020 | 4967 | 0.10 | Why? |
| Aged | 10 | 2021 | 215776 | 0.09 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.09 | Why? |
| Acute Disease | 1 | 2020 | 6029 | 0.09 | Why? |
| Workload | 1 | 2017 | 1887 | 0.08 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.08 | Why? |
| Neurology | 1 | 2018 | 1613 | 0.08 | Why? |
| Middle Aged | 9 | 2021 | 270681 | 0.08 | Why? |
| Humans | 22 | 2021 | 930598 | 0.08 | Why? |
| Quality of Health Care | 1 | 2017 | 1948 | 0.07 | Why? |
| Emergencies | 1 | 2020 | 4095 | 0.07 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.07 | Why? |
| Male | 11 | 2021 | 367725 | 0.07 | Why? |
| Hospitals, University | 1 | 2017 | 4173 | 0.07 | Why? |
| Aging | 1 | 2021 | 3581 | 0.07 | Why? |
| Echocardiography | 1 | 2018 | 3661 | 0.07 | Why? |
| Immunoassay | 1 | 2020 | 4485 | 0.07 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.07 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.06 | Why? |
| Nursing Staff, Hospital | 1 | 2017 | 1554 | 0.06 | Why? |
| Algorithms | 1 | 2020 | 7346 | 0.06 | Why? |
| Cardiology | 1 | 2018 | 2873 | 0.06 | Why? |
| Specimen Handling | 1 | 2020 | 6190 | 0.06 | Why? |
| Survival Rate | 1 | 2017 | 9206 | 0.06 | Why? |
| Follow-Up Studies | 3 | 2018 | 17020 | 0.06 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.06 | Why? |
| Patient Care Team | 1 | 2017 | 3556 | 0.06 | Why? |
| Patient Safety | 1 | 2017 | 4885 | 0.06 | Why? |
| Female | 9 | 2021 | 380317 | 0.06 | Why? |
| Predictive Value of Tests | 1 | 2017 | 9537 | 0.06 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.06 | Why? |
| Societies, Medical | 1 | 2018 | 6907 | 0.06 | Why? |
| Vitamin D | 1 | 2017 | 2904 | 0.06 | Why? |
| Adult | 7 | 2021 | 244371 | 0.06 | Why? |
| Myocardial Infarction | 1 | 2017 | 3361 | 0.05 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.05 | Why? |
| Heart Diseases | 1 | 2018 | 3503 | 0.05 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.05 | Why? |
| Health Policy | 1 | 2021 | 6242 | 0.05 | Why? |
| Infant | 2 | 2020 | 30274 | 0.05 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.05 | Why? |
| Gross Domestic Product | 1 | 2021 | 134 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.05 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.05 | Why? |
| Epidemics | 1 | 2020 | 6407 | 0.05 | Why? |
| Tertiary Care Centers | 1 | 2017 | 8248 | 0.05 | Why? |
| Length of Stay | 1 | 2017 | 11042 | 0.05 | Why? |
| Child, Preschool | 2 | 2020 | 36283 | 0.05 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.05 | Why? |
| Cone-Beam Computed Tomography | 1 | 2018 | 118 | 0.04 | Why? |
| Models, Economic | 1 | 2021 | 316 | 0.04 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.04 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.04 | Why? |
| HIV Seropositivity | 1 | 2020 | 320 | 0.04 | Why? |
| Radiotherapy Planning, Computer-Assisted | 1 | 2018 | 172 | 0.04 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.04 | Why? |
| Imatinib Mesylate | 1 | 2020 | 327 | 0.04 | Why? |
| Prognosis | 2 | 2018 | 32490 | 0.04 | Why? |
| International Classification of Diseases | 1 | 2019 | 265 | 0.04 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.04 | Why? |
| Heart Failure | 1 | 2017 | 6638 | 0.04 | Why? |
| Prospective Studies | 2 | 2018 | 43301 | 0.04 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.04 | Why? |
| Influenza, Human | 1 | 2019 | 10779 | 0.03 | Why? |
| Demography | 1 | 2021 | 1660 | 0.03 | Why? |
| Child | 2 | 2020 | 70012 | 0.03 | Why? |
| Delphi Technique | 1 | 2018 | 1257 | 0.03 | Why? |
| Treatment Outcome | 1 | 2020 | 51732 | 0.03 | Why? |
| Adolescent | 2 | 2020 | 86841 | 0.03 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.03 | Why? |
| Health Care Costs | 1 | 2021 | 1007 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.03 | Why? |
| Government | 1 | 2021 | 1453 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.03 | Why? |
| Cost-Benefit Analysis | 1 | 2021 | 2259 | 0.03 | Why? |
| Rectal Neoplasms | 1 | 1995 | 278 | 0.03 | Why? |
| Waste Water | 1 | 2021 | 2185 | 0.03 | Why? |
| Young Adult | 1 | 2020 | 93724 | 0.02 | Why? |
| Postoperative Care | 1 | 1995 | 755 | 0.02 | Why? |
| Cities | 1 | 2021 | 4937 | 0.02 | Why? |
| Interdisciplinary Communication | 1 | 2017 | 1425 | 0.02 | Why? |
| Adenocarcinoma | 1 | 1995 | 651 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2020 | 7220 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.02 | Why? |
| Retrospective Studies | 1 | 2017 | 105322 | 0.02 | Why? |
| Preoperative Care | 1 | 1995 | 1515 | 0.02 | Why? |
| Molecular Diagnostic Techniques | 1 | 2021 | 4239 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2018 | 3755 | 0.02 | Why? |
| Nursing Homes | 1 | 2021 | 4155 | 0.02 | Why? |
| Europe | 1 | 2021 | 12702 | 0.02 | Why? |
| Inpatients | 1 | 2019 | 5161 | 0.02 | Why? |
| Models, Theoretical | 1 | 2021 | 6659 | 0.01 | Why? |
| Mass Screening | 1 | 2021 | 8005 | 0.01 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.01 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.01 | Why? |
| Cytokines | 1 | 2020 | 15010 | 0.01 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.01 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.01 | Why? |
| Radiotherapy, Adjuvant | 1 | 1995 | 180 | 0.01 | Why? |
| Vaccination | 1 | 2019 | 19050 | 0.01 | Why? |
| Radiotherapy Dosage | 1 | 1995 | 428 | 0.01 | Why? |
| Disease-Free Survival | 1 | 1995 | 1654 | 0.01 | Why? |
| Hospitalization | 1 | 2019 | 54280 | 0.01 | Why? |
| Neoplasm Recurrence, Local | 1 | 1995 | 1063 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |